In Kenya, an east African country thousands of miles away, there is a black girl named Contecxin. Contecxin is not found in a dictionary in Kenya. It is the mother of the little girl in order to thank China for its anti-malaria. The drug, Ke Taixin, helped her drive away malaria and let her have a memory of her children.
Since the Chinese government sent its first aid to the African medical team in April 1963, Chinese medicine has established a bond with this mysterious continent. By the end of 2005, China had dispatched more than 15,000 medical team members to assist Africa. Chinese pharmaceutical companies have also invested in establishing pharmaceutical factories in countries such as Zanzibar, Mali, Cote d'Ivoire, Kenya, Egypt, and Sudan.
The African diplomatic ambassador in China once said that the next five to eight years will be the “golden age†for Chinese companies to invest in Africa. The economic complementarity between China and Africa is very strong and the potential for cooperation is huge. The Ministry of Commerce predicts that China-Africa trade volume will exceed 50 billion U.S. dollars in 2006 and achieve rapid growth for the fifth consecutive year.
Market attractive policy offers
Africa is a region that is seriously short of medicine and medicine, and most of its medicines are imported. As the overall level of economic development is still lagging, and the average per capita drug consumption level is relatively high among a few rich countries such as South Africa and Libya, the average per capita drug level in most African countries is very low, and many patients do not receive medical treatment. According to WHO data, the total number of AIDS victims in the continent has exceeded 20 million. Malaria is also prevalent in African countries. Diseases caused by various parasites such as schistosomiasis are widespread, and infectious diseases such as tuberculosis and cholera are high, causing millions of deaths every year. Therefore, the mortality rate of the African population ranks among the highest in the world. The pharmaceutical industry in Africa has a weak foundation. The pharmaceutical industry base in some countries except South Africa and Egypt is relatively better. The drugs produced in other African countries are mainly common antibiotics and antipyretic and analgesic drugs. The dosage forms are relatively simple, and local industries have no supporting conditions. The raw materials and packaging materials used to manufacture drugs depend on imports, and the drugs produced are basically consumed in the country. Taking Nigeria as an example, there are currently 160 pharmaceutical companies and the use of corporate equipment has long been maintained at 40%. Due to the lack of scientific research capacity and sufficient capital investment, the country can currently only produce simple generic drugs, and most of them are unbranded or patent expired drugs such as paracetamol, metronidazole, polymorpha, multivitamins, and analgesics. Agents, antibiotics, glucose, and saline.
According to the data from the National Export-Import Bank, at present, there are more than 800 companies in Africa that invest in Africa. From January to September this year, China-Africa trade volume reached 40.6 billion U.S. dollars, of which China's exports to Africa exceeded 18.7 billion U.S. dollars and imports from Africa exceeded 21.8 billion U.S. dollars. Dollars. As of the end of 2005, China’s investment in Africa had reached US$6.27 billion. It is precisely because of the huge demand for medicines and the poor supply capacity of African markets. In recent years, Africa has become one of the first choices for Chinese pharmaceutical companies to “go globalâ€. China Pharmaceutical Group, Guilin South Pharmaceutical of Shanghai Fosun Group, Kunming Pharmaceutical of Holley Group, Beijing Holley Cotai Pharmaceutical Co., Ltd. and so on successively invested in factories and set up marketing offices in Africa.
At present, China’s enterprises investing in Africa not only provide incentives and support policies such as concessional loans and preferential export buyer’s credit, but also set up investment development and trade promotion centers in 11 African countries. These centers are fully responsible for visas and commerce for Chinese entrepreneurs in Africa. The talks and other work have been signed with 25 countries in Africa.
As a health industry, pharmaceuticals in African countries also pay more attention to investment in the pharmaceutical industry. Various countries have successively introduced various preferential incentive policies. For example, some countries adopt tax-free measures for projects; they are exempted from corporate income tax for 5-10 years or even longer from the date of industrial operation or business start-up; equipment and other items invested in the project within the prescribed tax-exempt period and production Raw materials, junior-and-middle-level production materials, etc. are exempted from all duties and other import taxes; exempt from export taxes and industrial production taxes and other similar taxes and fees for all projects; and provide land and depreciation benefits for projects. In addition to the preferential policies granted by the governments of the countries where they are located, the cities under the jurisdiction also have some local preferential policies.
Since the Chinese government sent its first aid to the African medical team in April 1963, Chinese medicine has established a bond with this mysterious continent. By the end of 2005, China had dispatched more than 15,000 medical team members to assist Africa. Chinese pharmaceutical companies have also invested in establishing pharmaceutical factories in countries such as Zanzibar, Mali, Cote d'Ivoire, Kenya, Egypt, and Sudan.
The African diplomatic ambassador in China once said that the next five to eight years will be the “golden age†for Chinese companies to invest in Africa. The economic complementarity between China and Africa is very strong and the potential for cooperation is huge. The Ministry of Commerce predicts that China-Africa trade volume will exceed 50 billion U.S. dollars in 2006 and achieve rapid growth for the fifth consecutive year.
Market attractive policy offers
Africa is a region that is seriously short of medicine and medicine, and most of its medicines are imported. As the overall level of economic development is still lagging, and the average per capita drug consumption level is relatively high among a few rich countries such as South Africa and Libya, the average per capita drug level in most African countries is very low, and many patients do not receive medical treatment. According to WHO data, the total number of AIDS victims in the continent has exceeded 20 million. Malaria is also prevalent in African countries. Diseases caused by various parasites such as schistosomiasis are widespread, and infectious diseases such as tuberculosis and cholera are high, causing millions of deaths every year. Therefore, the mortality rate of the African population ranks among the highest in the world. The pharmaceutical industry in Africa has a weak foundation. The pharmaceutical industry base in some countries except South Africa and Egypt is relatively better. The drugs produced in other African countries are mainly common antibiotics and antipyretic and analgesic drugs. The dosage forms are relatively simple, and local industries have no supporting conditions. The raw materials and packaging materials used to manufacture drugs depend on imports, and the drugs produced are basically consumed in the country. Taking Nigeria as an example, there are currently 160 pharmaceutical companies and the use of corporate equipment has long been maintained at 40%. Due to the lack of scientific research capacity and sufficient capital investment, the country can currently only produce simple generic drugs, and most of them are unbranded or patent expired drugs such as paracetamol, metronidazole, polymorpha, multivitamins, and analgesics. Agents, antibiotics, glucose, and saline.
According to the data from the National Export-Import Bank, at present, there are more than 800 companies in Africa that invest in Africa. From January to September this year, China-Africa trade volume reached 40.6 billion U.S. dollars, of which China's exports to Africa exceeded 18.7 billion U.S. dollars and imports from Africa exceeded 21.8 billion U.S. dollars. Dollars. As of the end of 2005, China’s investment in Africa had reached US$6.27 billion. It is precisely because of the huge demand for medicines and the poor supply capacity of African markets. In recent years, Africa has become one of the first choices for Chinese pharmaceutical companies to “go globalâ€. China Pharmaceutical Group, Guilin South Pharmaceutical of Shanghai Fosun Group, Kunming Pharmaceutical of Holley Group, Beijing Holley Cotai Pharmaceutical Co., Ltd. and so on successively invested in factories and set up marketing offices in Africa.
At present, China’s enterprises investing in Africa not only provide incentives and support policies such as concessional loans and preferential export buyer’s credit, but also set up investment development and trade promotion centers in 11 African countries. These centers are fully responsible for visas and commerce for Chinese entrepreneurs in Africa. The talks and other work have been signed with 25 countries in Africa.
As a health industry, pharmaceuticals in African countries also pay more attention to investment in the pharmaceutical industry. Various countries have successively introduced various preferential incentive policies. For example, some countries adopt tax-free measures for projects; they are exempted from corporate income tax for 5-10 years or even longer from the date of industrial operation or business start-up; equipment and other items invested in the project within the prescribed tax-exempt period and production Raw materials, junior-and-middle-level production materials, etc. are exempted from all duties and other import taxes; exempt from export taxes and industrial production taxes and other similar taxes and fees for all projects; and provide land and depreciation benefits for projects. In addition to the preferential policies granted by the governments of the countries where they are located, the cities under the jurisdiction also have some local preferential policies.
Diversion Tube,Graphite Tube,Diversion Plate,Graphite Diversion Tube
Henan Carbons New Material Technology Co., Ltd. , https://www.kygraphiteparts.com